Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2B6rs2279343 Is Associated with Improved Survival of Pediatric Rhabdomyosarcoma Treated with Cyclophosphamide.

PloS one - 1 Jan 2016

Labib Rania M, A Abdelrahim Mohamed E, Elnadi Enas, Hesham Reem M, Yassin Dina

Abstract excerpt

BACKGROUND: Rhabdomyosarcoma (RMS) is a small round blue cell malignant tumor, representing 7% of childhood malignancies, and over 50% of all soft tissue sarcomas. Cyclophosphamide (CPA) is a prodrug and is the mainstay of RMS treatment. CYP2B6 is a highly polymorphic drug metabolizing enzyme involved in CPA bioactivation. The influence of CYP2B6 single nucleotide polymorphisms (SNPs) on the survival of RMS is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Algorithms
Share to Cyclophosphamide
Share to Cytochrome P-450 CYP2B6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Polymorphism, Restriction Fragment Length

Share to Prodrugs

Share to Rhabdomyosarcoma

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 27388155
DOI: 10.1371/journal.pone.0158890
PMCID: PMC4936837

Genes

EFS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2B6rs2279343 Is Associated with Improved Survival of Pediatric Rhabdomyosarcoma Treated with Cyclophosphamide.PMID 27388155Read ↗

Correlation of Genetic Polymorphism of CYP3A5 to Cyclophosphamide Efficacy and Toxicity in Rhabdomyosarcoma Pediatric Egyptian Cancer Patients.Semantic proximity Read ↗

Association between CYP2B6 genetic variability and cyclophosphamide therapy in pediatric patients with neuroblastomaSemantic proximity Read ↗

Efficacy and Toxicity of Vincristine and CYP3A5 Genetic Polymorphism in Rhabdomyosarcoma Pediatric Egyptian Patients.Semantic proximity Read ↗

CYP2B6 genetic variation in cyclophosphamide metabolism and hemorrhagic cystitis in Fanconi anemia patients undergoing allogeneic hematopoietic cell transplantationSemantic proximity Read ↗

Identification of genetic variants in pharmacokinetic genes associated with Ewing Sarcoma treatment outcome.Semantic proximity Read ↗

Analysis of CYP450 gene allelic variants can predict ifosfamide toxicity in Mexican paediatric patients.Semantic proximity Read ↗

Differential Expression of Cytochrome P450 Enzymes in Normal and Tumor Tissues from Childhood RhabdomyosarcomaSemantic proximity Read ↗

Pediatric Rhabdomyosarcoma: Epidemiology and Genetic SusceptibilitySemantic proximity Read ↗

Genetics, epigenetics and redox homeostasis in rhabdomyosarcoma: Emerging targets and therapeuticsSemantic proximity Read ↗

Infants and Newborns with Atypical Teratoid Rhabdoid Tumors (ATRT) and Extracranial Malignant Rhabdoid Tumors (eMRT) in the EU-RHAB Registry: A Unique and Challenging PopulationSemantic proximity Read ↗

The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomesSemantic proximity Read ↗

Cyclophosphamide pharmacogenomics and their effect on its bioactivation and pharmacokineticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.